Outlook
2023
Annual Industry Ranking And Forecast
Leadership
Exclusive interviews with the CEOs at bluebird bio and Voyager Therapeutics about what could be a standout 2023 for both firms, as well as a look at the life and career of Mads Øvlisen, former CEO of Novo Nordisk and father of CSR.
Flight Of The Navigator: Bluebird bio's Andrew Obenshain
For 12 years, bluebird bio has been developing gene therapies for rare genetic disease and now, with two approvals under its belt, the company is continuing to explore uncharted territory as it brings forward innovative new treatments. Holding the map is CEO Andrew Obenshain.
Al Sandrock On His First Mission At Voyager: Cracking The Tau Alzheimer’s Puzzle
Interview: Twelve months on from exiting Biogen, Al Sandrock is once again leading innovation in neuroscience, and hopes to crack the tau nut in Alzheimer’s and prove that Voyager’s next-generation gene therapy system will be a breakthrough.
Lessons From Novo Nordisk’s Mads Øvlisen, The Father Of CSR
When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.
Pfizer's Dolsten On Finding Ways To “Accelerate External Science”
Worldwide President of R&D Mikael Dolsten talked to Scrip about Pfizer's busy business development track record and the company's ambition to maintain its leadership in breast cancer.
Chapter sponsored by:
Driving More Effective Clinical Trials To Impact Lives
The blending of science and technology is changing the life sciences industry at an extraordinary pace. Clinical trials are getting more complex, both in design and in their conduct. Never before have we seen the growing number of systems and new technologies used within clinical research.
Outlook 2023 e-Book
Download a PDF copy of the Outlook 2023 collection, including Scrip 100 league tables.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.